COMMUNIQUÉS West-GlobeNewswire

-
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
05/06/2024 -
Hydreight in Partnership with DSV Global and VS Digital Health Launches Telemedicine Solution That Helps Companies Launch A D2C Healthcare Brand In All 50 States
05/06/2024 -
Telix Announces Launch of Proposed Initial Public Offering in the United States
05/06/2024 -
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
05/06/2024 -
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
05/06/2024 -
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
05/06/2024 -
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2024 -
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
05/06/2024 -
23andMe Launches New Genetic Report on Bipolar Disorder
05/06/2024 -
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
05/06/2024 -
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
05/06/2024 -
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
05/06/2024 -
LSL Pharma Group Announces a Combination of Private Placements for Maximum Aggregate Gross Proceeds of $4.5 Million
05/06/2024 -
Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
05/06/2024 -
GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
05/06/2024 -
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
05/06/2024 -
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
05/06/2024 -
Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference
05/06/2024 -
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
05/06/2024
Pages